- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04264546
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)
A Phase Ib Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell)
Studieoversigt
Detaljeret beskrivelse
The purpose of this phase Ib study is to evaluate the safety of a Sabin Inactivated Poliovirus Vaccine (sIPV) in adults and children, and the safety and immunogenicity of it in infants. 20 adults aged 18~45 years and 20 children aged 4 years were only administered one dose of sIPV with high D antigen content. 20 infants aged 2 months (60~90 days) were administered three doses of sIPV with high D antigen content, on the month 0, 1, 2 schedule. Serum samples were collected before the 1st dose and 30 days after the 3rd dose vaccination to assess the immunogenicity in infants. Adverse events occurring within 30 days after each dose were collected to assess the safety.
The antigen contents of type I, type II and type III polioviruses in the high-dose Sabin IPV were 22 DU, 65 DU and 65 DU. All vaccines were in liquid form, 0.5 ml per dose.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Nanjing, Kina
- Jiangsu Provincial Center for Disease Control and Prevention
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy volunteer aged 18~45 years with/without prior vaccination of poliovirus and without any contraindication for vaccination;
- Healthy volunteer aged 4 years with/without prior vaccination of poliovirus but without booster vaccination and any contraindication for vaccination;
- Healthy volunteer aged 2 months (60~90 days) without prior vaccination of poliovirus and any contraindication for vaccination;
- Guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;
- Complying with the requirement of the study protocol;
- Axillary temperature ≤ 37.0 °C;
Exclusion Criteria:
- Women aged 18~45 years with positive urine pregnancy test, pregnant or lactating women, or women with pregnancy plans within 3 months;
- Preterm or low birth weight infants;
- Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
- History of polio;
- Severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;
- History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
- Autoimmune disease or immunodeficiency/immunosuppressive;
- Bleeding disorder diagnosed by a doctor (e.g., coagulation factor deficiency, coagulation disorder, or platelet disorder), or significant bruising or coagulopathy;
- Serious chronic diseases, respiratory diseases, cardiovascular diseases, liver or kidney diseases or skin diseases;
- Mother of the participant has HIV infection;
- Acute illness or acute exacerbation of chronic disease within the past 7 days;
- Had a high fever within the past 3 days (axillary temperature ≥ 38.0°C);
- Receipt of any subunit or inactivated vaccine within the past 7 day;
- Receipt of any live attenuated vaccine within the past 14 days;
- Receipt of any blood product within the past 3 months;
- Any other factor that, in the judgment of the investigator, suggesting the volunteer is unsuitable for this study;
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Experimental Adult Group - High dosage
One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
|
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD.
The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU.
The vaccine was in liquid form, 0.5 ml per dose.
|
Eksperimentel: Experimental Children Group - High dosage
One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
|
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD.
The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU.
The vaccine was in liquid form, 0.5 ml per dose.
|
Eksperimentel: Experimental Infant Group - High dosage
Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
|
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD.
The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU.
The vaccine was in liquid form, 0.5 ml per dose.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Serokonverteringsraterne (SCR'er) for hver gruppe 30 dage efter tre-dosis regime
Tidsramme: 28-42 dage
|
Individer, hvis præimmune antistofniveau < 1:8 og postimmunt antistofniveau ≥ 1:8, eller dem, hvis præimmune antistofniveau ≥ 1:8 og stigningen af postimmunt antistofniveau ≥ 4 gange, betragtes som serokonverterede.
|
28-42 dage
|
The geometric mean titer (GMT) of each group 30 days after three-dose regimen
Tidsramme: 28~42 days
|
GMT of each group 28~42 days after three-dose regimen
|
28~42 days
|
The geometric mean fold increase (GMI) of each group 30 days after three-dose regimen
Tidsramme: 28~42 days
|
The GMI is the increase of post-immune GMT from pre-immune GMT
|
28~42 days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
The incidences of adverse reactions of each group occurred within 30 days after each injection
Tidsramme: 30 days
|
The number of participants who had adverse reactions divided by the number of all participants
|
30 days
|
The incidences of adverse events (AEs) of each group occurred within 30 days after each injection
Tidsramme: 30 days
|
The number of participants who had adverse events (AEs) divided by the number of all participants
|
30 days
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 2017L00935-1
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Polio
-
Aga Khan UniversityBill and Melinda Gates Foundation; World Health Organization; UNICEF; Peshawar... og andre samarbejdspartnereUkendtPolio | Polio Sero Konvertering | Polio Sero-prævalens | VaccinationsdækningPakistan
-
Instituto Nacional de Saúde, MozambiqueWorld Health OrganizationAfsluttet
-
Zhejiang Provincial Center for Disease Control...China National Biotec Group Company LimitedAfsluttet
-
Stanford UniversityBill and Melinda Gates Foundation; Instituto Nacional de Salud Publica,...Afsluttet
-
Vaxtrials S.A.Bill and Melinda Gates FoundationAfsluttet
-
Istanbul Physical Medicine Rehabilitation Training...AfsluttetTræthed | Polio | Polio og post-polio syndromKalkun
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdAfsluttet
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdAfsluttetPolio og post-polio syndromKina
-
Calliditas Therapeutics ABAfsluttetPost Polio Syndrom, PPSSverige
Kliniske forsøg med sIPV
-
Institute of Medical Biology, Chinese Academy of...Yunnan Center for Disease Control and PreventionAfsluttet
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Hubei Provincial Center... og andre samarbejdspartnereUkendt
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdAfsluttet
-
Sinovac Biotech Co., LtdAfsluttet
-
China National Biotec Group Company LimitedPeking University; Beijing Institute of Biological Products Co Ltd.; Sichuan... og andre samarbejdspartnereUkendt
-
Sinovac Biotech Co., LtdAfsluttet
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdAfsluttetPolio og post-polio syndromKina
-
Sinovac Biotech Co., LtdIkke rekrutterer endnu
-
Sinovac Biotech Co., LtdAfsluttet
-
Sinovac Biotech Co., LtdAfsluttet